Pharsight

Temodar patents expiration

TEMODAR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5260291 MERCK SHARP DOHME Tetrazine derivatives
Aug, 2013

(10 years ago)

US5260291

(Pediatric)

MERCK SHARP DOHME Tetrazine derivatives
Feb, 2014

(10 years ago)

US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents
Feb, 2023

(1 year, 2 months ago)

US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents
Feb, 2023

(1 year, 2 months ago)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Sep, 2023

(7 months ago)

Temodar is owned by Merck Sharp Dohme.

Temodar contains Temozolomide.

Temodar has a total of 5 drug patents out of which 5 drug patents have expired.

Expired drug patents of Temodar are:

  • US5260291
  • US5260291*PED
  • US7786118
  • US8623868
  • US6987108

Temodar was authorised for market use on 27 February, 2009.

Temodar is available in capsule;oral, powder;intravenous dosage forms.

Temodar can be used as treatment of malignant neoplasm.

The generics of Temodar are possible to be released after 08 September, 2023.

Drugs and Companies using TEMOZOLOMIDE ingredient

Market Authorisation Date: 27 February, 2009

Treatment: Treatment of malignant neoplasm

Dosage: POWDER;INTRAVENOUS; CAPSULE;ORAL

How can I launch a generic of TEMODAR before it's drug patent expiration?
More Information on Dosage

TEMODAR family patents

Family Patents